Immune to Cancer: The CRI Blog
-
AACR 2022 Recap: T Cells Still On Top, But Make Room for Myeloid Cells
At the 2022 AACR annual meeting, CRI scientists highlighted a wide scope of cancer immunology advances, and…
-
Ira Mellman Receives 2022 AACR-CRI Lloyd J. Old Award in Cancer Immunology
Dr. Ira Mellman, a longtime member of the CRI Scientific Advisory Council, received CRI’s highest scientific career…
-
AACR 2022 Preview: Decoding Cancer Complexity, Integrating Science, and Transforming Patient Outcomes
During AACR’s upcoming 2022 annual meeting, CRI scientists will share the latest advances in cancer immunotherapy.
-
AACR21 Recap: CRI Scientists Highlight the Latest in ‘Discovery Science Driving Clinical Breakthroughs’
During AACR21, CRI scientists highlighted how improving our understanding of basic immune biology may enable improved immunotherapies…
-
CRI Speaks with Dr. Steven A. Rosenberg, Winner of the 2020 AACR-CRI Lloyd J. Old Award in Cancer Immunology
Dr. Steven A. Rosenberg receives the 2020 AACR-CRI Lloyd J. Old Award in Cancer Immunology on June…
-
AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights
The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…
-
AACR20 Day 1 Highlights: Breast Cancer, Lung Cancer, and the Microbiome
The first day of the 2020 AACR Annual Meeting shared latest data from immunotherapy clinical trials in…
-
AACR19 Recap: Leveraging the Latest Science to Improve Clinical Care
AACR19 highlighted incredible advances in our efforts to leverage cutting-edge science in order to improve medical treatment for…
-
AACR19 Day 5 Update: Bispecific Antibodies, the Importance of “Helper” T Cells, and the Lloyd J. Old Award Lecture
Scientists tackled novel immunotherapy strategies that could potentially enable more patients with more types of cancer to…